What is Zacks Research’s Estimate for HURA FY2026 Earnings?

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Equities researchers at Zacks Research increased their FY2026 EPS estimates for TuHURA Biosciences in a research report issued to clients and investors on Tuesday, August 25th. Zacks Research analyst J. Vandermosten now anticipates that the company will post earnings per share of ($0.57) for the year, up from their prior estimate of ($0.64). The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.57) per share.

HURA has been the subject of a number of other reports. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Friday, July 17th. Citizens Jmp reiterated a “market outperform” rating and issued a $9.00 price objective on shares of TuHURA Biosciences in a research report on Tuesday, August 18th. Finally, Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.00.

TuHURA Biosciences Stock Performance

NASDAQ HURA opened at $2.13 on Friday. TuHURA Biosciences has a 1 year low of $0.41 and a 1 year high of $3.43. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.18 and a quick ratio of 0.18. The stock has a market capitalization of $135.74 million, a PE ratio of -3.94 and a beta of -0.01. The company’s 50 day simple moving average is $2.27 and its two-hundred day simple moving average is $2.11.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01.

Hedge Funds Weigh In On TuHURA Biosciences

A number of institutional investors have recently made changes to their positions in HURA. Virtu Financial LLC bought a new position in shares of TuHURA Biosciences in the 3rd quarter worth $26,000. JPMorgan Chase & Co. bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth $27,000. Wells Fargo & Company MN grew its position in TuHURA Biosciences by 109.0% in the fourth quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock worth $29,000 after acquiring an additional 19,931 shares in the last quarter. Invesco Ltd. bought a new position in TuHURA Biosciences in the second quarter valued at $30,000. Finally, Goldman Sachs Group Inc. bought a new position in TuHURA Biosciences in the fourth quarter valued at $30,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.